VTYX News and Press, Ventyx Biosciences Inc. From 03/14/24

NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Ventyx Biosciences, Inc. (NASDAQ: VTYX)? Did you purchase your shares pursuant and/or traceable to the Company’s October 21, 2021 IPO, or between October 21, 2021 and ...

2024-03-12 08:27:34 ET More on Ventyx Biosciences Ventyx Pivots To Obesity Amid Transformation Ventyx: Too Risky Right Now After Some Poor Data Ventyx stock tumbles 18% amid pipeline updates Ventyx gains after $100M private placement Seeking Alpha...

2024-03-12 08:05:10 ET More on pre-market gainers & stock ZTO Express: Expecting In-Line Fourth Quarter Results KE Holdings: Real-Time Proxy Of China's Property Market Seeking Alpha’s Quant Rating on KE Holdings Historical earnings data for KE Hold...

2024-03-12 07:43:50 ET Summary Ventyx's stock plummeted from over $30/share to $2/share after disappointing data for VTX958, prompting workforce reductions. VTX3232 shows promise in preclinical trials for obesity and Parkinson's, with a trial on obesity planned for the second half...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ventyx To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - March 11, 2024) - Faruqi & Faruqi, LLP, a leading national se...

2024-03-11 12:49:34 ET Gainers: Kidpik Corp ( PIK ) +118% . TC BioPharm ( TCBP ) +94% . L.S. Starrett Co. ( SCX ) +59% . Kingsoft Cloud Holdings Ltd ( KC ) +33% . Energem Corp ( ENCP ) +31% . NextNav ( NN ) +28% . ...

2024-03-11 11:28:30 ET More on Ventyx Biosciences Ventyx: Too Risky Right Now After Some Poor Data Ventyx gains after $100M private placement Microcap ZyVersa up 71% on study supporting new way to fight obesity Seeking Alpha’s Quant Rating on Ventyx Bi...

2024-03-11 10:00:56 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Waters, Moderna most shorted ...

VTX3232 was well-tolerated in the Phase 1 trial with robust target coverage achieved in both plasma and CSF; Ventyx is planning to initiate Phase 2a trials in Parkinson’s disease and obesity in H2 2024 Topline Phase 2 data for VTX2735 in CAPS patients establish clinical proof of ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ventyx To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - March 8, 2024) - Faruqi & Faruqi, LLP, a leading national sec...